These results pointed to Vox2 as a potential oral adjuvant pharmacotherapy for insulin in the treatment of type 1 diabetes, promoting improvement in glycemic control associated with a reduction in insulin dose and pancreatic antioxidant status. This evidence concerns the gene INS and type 1 diabetes mellitus.